Opsoclonus Myoclonus Syndrome is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Opsoclonus-Myoclonus Syndrome (OMS)[1], also known as Opsoclonus-Myoclonus-Ataxia (OMA) or "dancing eyes-dancing feet" syndrome, is a rare neuroimmune disorder[2] characterized by a triad of symptoms: opsoclonus (rapid, involuntary, multi-directional eye movements), myoclonus (sudden, involuntary muscle jerks), and ataxia (loss of coordination)[1:1]. This syndrome represents an important intersection ofautoimmunity, neuroinflammation, and neurodegeneration, with significant implications for understanding paraneoplastic neurological syndromes. [2:1]
Opsoclonus-Myoclonus Syndrome is a complex neurological disorder that can affect individuals of any age, though it most commonly presents in children between 1-4 years of age. In pediatric cases, OMS is frequently associated with underlying neuroblastoma[3] (a neural crest tumor), earning it the classification as a paraneoplastic neurological syndrome. In adults, OMS may be associated with various malignancies including small cell lung cancer, breast cancer, or ovarian teratomas, or may occur without identifiable tumor association (idiopathic). [3:1]
The syndrome is considered an autoimmune disorder[4] in which the immune system mistakenly attacks neural tissues, particularly in the cerebellum and brainstem regions responsible for motor control and eye movement coordination. This autoimmune attack leads to the characteristic neurological symptoms and can result in long-term cognitive and behavioral sequelae if not adequately treated. [4:1]
OMS is a rare condition with an estimated annual incidence of approximately 0.27-0.5 cases per million[5] population in children. The peak incidence occurs in early childhood, with most cases diagnosed between 18 months and 3 years of age. There appears to be a slight female predominance in pediatric cases, with a female-to-male ratio of approximately 1.5:1. In adults, the syndrome is even rarer, with most cases reported in individuals between 20-50 years of age. [5:1]
Approximately 50-60% of pediatric OMS cases are associated with neuroblastoma, making it one of the most common paraneoplastic neurological syndromes in children. The remaining cases are classified as idiopathic or post-infectious in origin. In adults, approximately 20-30% of OMS cases are associated with underlying malignancies. [^6]
The pathogenesis of OMS involves a dysregulated immune response that targets neuronal antigens, particularly those expressed in the cerebellum, brainstem, and spinal cord. Several immune mechanisms have been implicated: [^7]
B-cell mediated autoimmunity: Patients with OMS produce autoantibodies against neuronal antigens. While no single specific antibody has been consistently identified, candidates include antibodies against: [^8]
T-cell mediated cytotoxicity: CD8+ T lymphocytes have been shown to infiltrate affected neural tissues, suggesting cell-mediated autoimmune damage. The T-cell response may be directed against neural antigens or may represent molecular mimicry between tumor antigens and neuronal proteins. [^9]
Cytokine dysregulation: Elevated levels of pro-inflammatory cytokines including IL-6, TNF-α, and IFN-γ have been documented in OMS patients, indicating a systemic inflammatory component. [^10]
In paraneoplastic OMS, the tumor expresses neuronal antigens that trigger an immune response. The immune system attacks both the tumor and the nervous system due to cross-reactivity (molecular mimicry). Neuroblastoma cells, which arise from sympathetic nervous system precursors, naturally express neural antigens that can trigger this cross-reactive immune response. [^11]
The hallmark symptoms of OMS include: [^12]
Opsoclonus: [^13]
Myoclonus: [^14]
Ataxia: [^15]
Beyond the classic triad, patients may experience:
In paraneoplastic cases, symptoms related to the underlying tumor may be present:
Diagnosis of OMS is primarily clinical, based on recognition of the characteristic triad:
The presence of all three symptoms establishes the diagnosis. In incomplete presentations, two of three core features plus supporting evidence (paraneoplastic antibodies, tumor) can establish the diagnosis.
Neurological examination: Assessment of eye movements, coordination, gait, and muscle tone
Imaging studies:
Laboratory studies:
Tumor screening:
Electrophysiology:
First-line treatment for OMS involves aggressive immunotherapy:
Corticosteroids: High-dose intravenous methylprednisolone pulses followed by oral prednisone taper
Intravenous immunoglobulin (IVIG): Modulates immune response, often used in combination with steroids
Rituximab: Anti-CD20 monoclonal antibody depletes B-cells, showing significant efficacy in steroid-dependent or refractory cases
Cyclophosphamide: Alkylating agent used in severe or refractory cases
Plasma exchange: May provide rapid improvement in acute severe cases
In paraneoplastic cases, tumor resection is crucial:
A typical treatment algorithm includes:
With modern aggressive immunotherapy, prognosis has improved significantly:
Neurological recovery:
Cognitive outcomes:
Relapse risk:
With appropriate treatment and tumor management, mortality is primarily related to the underlying malignancy rather than neurological complications. In idiopathic or non-paraneoplastic cases, prognosis is generally favorable with aggressive immunotherapy.
Current research focuses on:
The study of Opsoclonus Myoclonus Syndrome has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.
Dengue-triggered opsoclonus myoclonus ataxia syndrome in an infant. ↩︎ ↩︎
HLA and T-Cell Receptor Investigations in Idiopathic and Paraneoplastic Opsoclonus-Myoclonus in Children. ↩︎ ↩︎
Case Report and Literature Review of Mycoplasma Pneumoniae Associated Opsoclonus-Myoclonus-Ataxia Syndrome. ↩︎ ↩︎
Prolonged Diagnostic Latency and Long-term Surveillance in Anti-Ri Antibody-positive Opsoclonus-myoclonus Syndrome with Carcinoma of Unknown Primary. ↩︎ ↩︎
Opsoclonus-myoclonus syndrome with anti-SOX1 antibodies. ↩︎ ↩︎